
The White House withdrew Heidi Overton's nomination to lead the Food and Drug Administration one day before a Senate committee was due to decide whether to advance it. ANSA reported that the nomination lacked sufficient Senate support, including among some Republicans.
That makes the withdrawal more than a procedural delay. The scheduled committee consideration was imminent, and the objections had already surfaced in public. Republican senator Bill Cassidy, who chairs the Senate committee on Health, Education, Labor and Pensions, had voiced reservations about Overton's limited management experience.
ANSA also reported that senators from both parties criticised Overton's position on childhood vaccines and questioned whether she would distance herself from the views of Health Secretary Robert Kennedy Jr. The reported objections therefore extended beyond a single party dispute: they concerned both the management credentials expected of an FDA leader and the nominee's approach to an issue central to public health.
Withdrawing the nomination prevents those divisions from immediately becoming a committee decision on whether to move it forward. The available material does not identify who may lead the FDA after the withdrawal, whether the White House will nominate someone else, or what regulatory direction might follow. It does, however, explain the timing of the decision: Overton's nomination no longer had enough reported Senate support to proceed.
Sources
- ANSA · Top news · Source date: 2026-11-18
Independent editorial content. WUA is not affiliated with any political party. 2026-11-18